• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

    9/26/24 4:01:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVTX alert in real time by email

    SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study. Patients currently enrolled in pegtibatinase studies continue to receive study medication from small scale batches which are unaffected by the scale-up process. Currently enrolled patients will be able to continue on study medication as scheduled for the duration of the trials they are participating in.

    The voluntary enrollment pause was enacted following the Company's determination that the desired drug substance profile was not achieved in the recent scale-up process. The Company is in the process of notifying all study investigators of the decision to pause enrollment of new patients into the study until additional material is available.

    "We believe the potential for pegtibatinase to become the first disease-modifying therapy for classical HCU remains unchanged. Our internal team and external manufacturing partners have extensive biologics expertise, and we are confident that we will be able to make the necessary manufacturing process improvements to continue with this pivotal program. We remain committed to supporting the patients currently enrolled in our clinical trials while working with our manufacturing partners to optimize our commercial-scale manufacturing process," said Bill Rote, Ph.D., senior vice president of research and development at Travere Therapeutics.

    The Company expects to further evaluate the necessary commercial process improvements to enable the continuation of the Phase 3 program and anticipates the earliest date to restart enrollment in the Phase 3 HARMONY Study will be in 2026. Previously planned investments related to clinical enrollment in HARMONY and large-scale production are expected to be delayed beyond 2025. Together with the expected decline in costs associated with the development of sparsentan as the Phase 3 programs advance towards completion, the Company now estimates that research and development expenses may be reduced by more than $30 million in 2025 compared to 2024. The Company continues to anticipate that its cash, cash equivalents and marketable securities of $325.4 million as of June 30, 2024 can support its operations into 2028.

    Conference call information

    Travere Therapeutics will host a conference call and webcast today, Thursday, September 26, 2024 at 4:30 p.m. ET to discuss the voluntary pause in enrollment. To participate in the conference call, dial +1 (323) 994-2093 (U.S.) or +1 (888) 394-8218 (International), confirmation code 5880214. The webcast can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website.

    About Classical Homocystinuria

    Classical homocystinuria (HCU) is a rare genetic metabolic disorder caused by a deficiency in the enzyme cystathionine beta synthase (CBS). CBS is a pivotal enzyme that is essential for the management of methionine and cysteine in the body. Classical HCU leads to toxic levels of homocysteine that can result in life-threatening thrombotic events such as stroke, pulmonary embolism and deep vein thrombosis, ophthalmologic and skeletal complications, as well as developmental delay. Current treatment options are limited to protein-restricted diet and use of vitamin B6 and betaine.

    About Pegtibatinase

    Pegtibatinase is an investigational PEGylated, recombinant enzyme replacement therapy designed to address the underlying cause of classical HCU. In preclinical studies, pegtibatinase has demonstrated an ability to reduce total homocysteine levels and improve clinical parameters. In December 2023 the Company initiated the pivotal Phase 3 HARMONY Study to support the potential approval of pegtibatinase for the treatment of classical HCU. The HARMONY Study is a global, randomized, multi-center, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of pegtibatinase as a novel treatment to reduce total homocysteine (tHcy) levels. In May 2023 the Company announced that data from four patients treated with the highest dose of pegtibatinase in the Phase 1/2 COMPOSE Study showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment. To date, the pegtibatinase program has been granted Breakthrough Therapy designation, Rare Pediatric Disease and Fast Track designations by the FDA, as well as Orphan Drug designation in the U.S. and Europe.

    About Travere Therapeutics

    At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words "on-track," "positioned," "look forward to," "will," "would," "may," "might," "believes," "anticipates," "plans," "expects," "intends," "potential," or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: the potential for pegtibatinase to become the first disease-modifying therapy for classical HCU; statements and expectations regarding future process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study, and related timing expectations; statements regarding ongoing clinical trials, including statements regarding medication for patients currently enrolled in such trials; and statements and expectations related to future research and development expenses and the expected timing thereof, including with respect to investments related to clinical enrollment in HARMONY and large scale production, and the expected decline in costs associated with the development of sparsentan as the Phase 3 programs advance towards completion; and expectations regarding cash runway. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with manufacturing processes and improvements, and risks related to the regulatory review and approval process, as well as risks and uncertainties associated with the Company's business and finances in general, the success of its commercial products and risks and uncertainties associated with its preclinical and clinical stage pipeline. Specifically, the Company faces risks associated with the challenges of manufacturing scale-up, the ongoing commercial launch of FILSPARI, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, as well as risks associated with the successful development and execution of commercial strategies for such products. The risks and uncertainties the Company faces with respect to its preclinical and clinical stage pipeline include risk that the Company's clinical candidates will not be found to be safe or effective and that current or anticipated future clinical trials will not proceed as planned. The Company also faces the risk that its cash runway might not last as long as currently anticipated and the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company's dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company's products, and technological changes that may limit demand for the Company's products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading "Risk Factors", as included in the Company's most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.

    Contact Info

    Media:

    888-969-7879                                        

    [email protected]

    Investors:

    888-969-7879                                        

    [email protected]



    Primary Logo

    Get the next $TVTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TVTX

    DatePrice TargetRatingAnalyst
    6/11/2025$30.00Buy
    H.C. Wainwright
    6/11/2025$35.00 → $32.00Buy
    Citigroup
    1/10/2025Overweight
    Cantor Fitzgerald
    10/21/2024$9.00 → $27.00Equal Weight → Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$25.00Neutral → Buy
    Guggenheim
    3/27/2024Buy → Neutral
    Guggenheim
    12/5/2023$7.00 → $10.00Neutral → Buy
    Citigroup
    More analyst ratings

    $TVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Inrig Jula sold $11,940 worth of shares (815 units at $14.65), decreasing direct ownership by 0.91% to 88,787 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      7/2/25 5:28:57 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Williams Brinkley Ruth was granted 6,500 shares, increasing direct ownership by 34% to 25,750 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/16/25 7:00:22 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Poole Sandra was granted 6,500 shares, increasing direct ownership by 28% to 30,000 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/16/25 7:00:18 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Travere Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Travere Therapeutics with a rating of Buy and set a new price target of $30.00

      6/11/25 7:55:49 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Travere Therapeutics with a new price target

      Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $32.00 from $35.00 previously

      6/11/25 7:31:38 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Travere Therapeutics

      Cantor Fitzgerald initiated coverage of Travere Therapeutics with a rating of Overweight

      1/10/25 9:14:01 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    SEC Filings

    See more
    • SEC Form S-8 filed by Travere Therapeutics Inc.

      S-8 - Travere Therapeutics, Inc. (0001438533) (Filer)

      6/17/25 5:11:56 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Travere Therapeutics, Inc. (0001438533) (Filer)

      5/16/25 4:13:55 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Travere Therapeutics, Inc. (0001438533) (Filer)

      5/15/25 4:29:26 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 81,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant dat

      6/12/25 5:00:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

      New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025. The Company will present new data evaluating biomarkers of disease progression in IgA nephropathy (IgAN) from the Phase 2 SPARTAN Study showing rapid and sustained reductions in urinary BAFF and sC5b9 as well as reductions in proinflammatory and profibrotic biomarkers after starting FILS

      6/11/25 7:01:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

      Grammy-winning producer and platinum recording artist joins forces with patient advocate and singer-songwriter to transform the invisible struggle of FSGS into a creative movement New campaign aims to unite the FSGS community and inspire patients and caregivers to share their journeys Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the launch of a new awareness campaign, "Play It Forward," to bring hope and encouragement to the focal segmental glomerulosclerosis (FSGS) community. FSGS is a rare kidney disease (RKD) affecting children and adults and a leading cause of kidney failure. This press release features multimedia. View the full release here: https://www.businesswire.co

      6/10/25 7:00:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

      Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm

      7/11/22 8:00:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

      Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

      3/23/22 7:30:00 AM ET
      $ATRA
      $NTRA
      $TVTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

      SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics

      1/4/22 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 5:13:38 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Travere Therapeutics Inc.

      SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 1:01:01 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 9:46:28 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Financials

    Live finance-specific insights

    See more
    • Travere Therapeutics Reports First Quarter 2025 Financial Results

      Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to full approval for the treatment of IgAN in Europe and the UK Clinical data presented at the National Kidney Foundation Spring Clinical Meetings reinforced FILSPARI's foundational position in IgAN and potential in FSGS Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $322 million Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2025 financial results and provided a corporate update. "As the only fully approve

      5/1/25 4:01:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Report First Quarter 2025 Financial Results

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company

      4/24/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics,

      2/13/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care